J&J: to present new data in neuropsychiatry

(CercleFinance.com) - Johnson & Johnson has announced that 23 abstracts, presenting clinical and real-world data from its neuropsychiatry portfolio, will be presented at the annual Psych Congress from 29 October to 2 November in Boston.


Presentations will include new data on the safety and efficacy of Spravato (esketamine) for schizophrenia.

Presentations will also include five-year safety data on Spravato in 35,000 adults, confirming its well-established safety profile; insights into the burden of anhedonia in adults with major depression; and an analysis of 30,000 adults with schizophrenia, showing the link between symptom relapse and risk of premature death.

Johnson & Johnson confirms its commitment to mental health research to better understand and treat complex disorders such as major depression and schizophrenia, the company says.


Copyright (c) 2024 CercleFinance.com. All rights reserved.